ZEPOSIA was compared to a leading injectable medicine (Avonex) in two separate clinical studies.*
Explore the results
ZEPOSIA was compared to a leading injectable medicine (Avonex) in two separate clinical studies.*
Explore the results
People taking ZEPOSIA had an ARR of
0.181 vs 0.350 with a leading injectable.
People taking ZEPOSIA had
an ARR of
0.172 vs 0.276
with a leading injectable.
Annualized Relapse Rate (ARR) is the average number of relapses a group of people has in one year. A total of 895 people were in this study (ZEPOSIA 447, a leading injectable 448). A total of 874 people were in this study (ZEPOSIA 433, a leading injectable 441).
A total of 895 people were in this study (ZEPOSIA 447, a leading injectable 448). A total of 874 people were in this study (ZEPOSIA 433, a leading injectable 441).
†A relapse was defined as new or worsening symptoms directly associated with MS that lasted more than twenty-four hours (after having a mostly stable neurological state for at least thirty days).
A method used to measure disability in multiple sclerosis and monitor changes in the level of disability over time.
T2 (lesions) refers to a type of
magnetic resonance imaging (MRI)
scan (a T2-weighted image) that can
be used to identify the total
number of lesions a person has.
People taking ZEPOSIA had an average of
1.47 lesions (T2) vs 2.84 with a leading injectable.
People taking ZEPOSIA had an average of
1.84 lesions (T2) vs 3.18 with a leading injectable.
A total of 895 people were in this study (ZEPOSIA 447, a leading injectable 448). A total of 874 people were in this study (ZEPOSIA 433, a leading injectable 441).
T1 Gadolinium (Gd)-enhancing lesions are areas of active inflammation that show current MS activity in the brain.
People taking ZEPOSIA had an average of 0.16 lesions (T1 Gd-enhancing) vs 0.43 with a leading injectable.
People taking ZEPOSIA had an average of 0.18 lesions (T1 Gd-enhancing) vs 0.37 with a leading injectable.
A total of 895 people were in this study (ZEPOSIA 447, a leading injectable 448). A total of 874 people were in this study (ZEPOSIA 433, a leading injectable 441).
I’ve been taking ZEPOSIA for a year now, and my doctor and I are happy with my results.”
—Melissa
A real patient compensated for her time.
(Individual results may vary.)
In two separate clinical studies, a
The two clinical studies, when combined, were one of the largest studies to compare one MS medication to another (not a placebo).
Together, the two studies included
1,769 people in total:
Each of the two clinical studies for ZEPOSIA was randomized, which means that participants were chosen randomly to receive either ZEPOSIA or a leading injectable medicine. The studies were also double-blind, so neither the professionals giving the medication nor the people taking it were told which medication was being administered.
T1 Gd-enhancing lesions are areas of active inflammation that show current MS activity in the brain.
The average age across both studies was
In both studies combined, approximately
The safety of ZEPOSIA was evaluated in two separate clinical studies. Learn about the side effects that were reported.
Sign up to receive the latest ZEPOSIA details, stories from real people taking ZEPOSIA, and more from ZEPOSIA 360 Support™.
*Avonex® (interferon beta-1a).
Collapse
–
Do not take ZEPOSIA if you:
Talk to your healthcare provider before taking ZEPOSIA if you have any of these conditions or do not know if you have any of these conditions.
ZEPOSIA may cause serious side effects, including:
Call your healthcare provider right away if you have any of these symptoms of an infection during treatment with ZEPOSIA and for 3 months after your last dose of ZEPOSIA:
Your healthcare provider may delay starting or may stop your ZEPOSIA treatment if you have an infection.
Progressive multifocal leukoencephalopathy (PML). ZEPOSIA can increase your risk for PML, which is a rare brain infection that usually leads to death or severe disability. If PML happens, it usually happens in people with weakened immune systems but has happened in people who do not have weakened immune systems. Symptoms of PML get worse over days to weeks. Call your doctor right away if you have any new or worsening symptoms of PML that have lasted several days, including: weakness on one (1) side of your body, changes in your vision, changes in your thinking or memory, confusion, changes in your personality, loss of coordination in your arms or legs, decreased strength, and/or problems with balance.
Call your healthcare provider if you experience the following symptoms of slow heart rate:
Follow directions from your healthcare provider when starting ZEPOSIA and when you miss a dose.
Continue reading for additional possible serious side effects of ZEPOSIA.
Before taking ZEPOSIA, tell your healthcare provider about all of your medical conditions, including if you:
Tell your healthcare provider about all the medicines you take or have recently taken, including prescription and over-the-counter medicines, vitamins, and herbal supplements. Using ZEPOSIA with other medicines can cause serious side effects. Especially tell your healthcare provider if you take or have taken:
You should not receive live vaccines during treatment with ZEPOSIA, for at least 1 month before taking ZEPOSIA and for 3 months after you stop taking ZEPOSIA. Vaccines may not work as well when given during treatment with ZEPOSIA.
ZEPOSIA can cause serious side effects, including:
The most common side effects of ZEPOSIA can include:
These are not all of the possible side effects of ZEPOSIA. For more information, ask your healthcare provider or pharmacist.
Call your healthcare provider for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.
Multiple Sclerosis (MS): ZEPOSIA® (ozanimod) is a prescription medicine used to treat relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults.
Ulcerative Colitis (UC): ZEPOSIA is a prescription medicine used to treat moderately to severely active ulcerative colitis (UC) in adults.
It is not known if ZEPOSIA is safe and effective in children.
Please see full Prescribing Information, including Medication Guide.
+
Do not take ZEPOSIA if you: